AveXis Presents Positive Interim Results on Zolgensma Across a Broad Spectrum of Patients with SMA

07 May 2019 / Posted in: Treatments & Research

AveXis presented positive results from clinical trials on Zolgensma, across a broad spectrum of patients with SMA at the 2019 American Academy of Neurology conference in Philadelphia.

Read full story

Data Published in Neurology Suggest Long-Term Benefits of Spinraza™ Treatment in Later-Onset SMA

07 May 2019 / Posted in: Treatments & Research

Biogen has announced that data from a study on the safety and tolerability of Spinraza™ in individuals with later-onset SMA had been published in the peer-reviewed journal, Neurology.

Read full story

Education Secretary Seeking Views On Funding For Children With Special Needs

03 May 2019 / Posted in: Information, Support

Damian Hinds is at a conference of the National Association of Head Teachers today where he is expected to make an announcement calling for a fresh look at educational funding for children with special needs in England.

Read full story

Response From Biogen to SMA UK & MDUKs' Letter

03 May 2019 / Posted in: Treatments & Research

Following SMA UK and MDUK sending letters urging Biogen, NHS England and NICE to work strenuously this week so that the NICE committee can endorse an agreement for access to nusinersen for all with SMA Types 1, 2 & 3, we have received a response from Biogen.

Read full story

SMA UK and MDUK write to NICE, NHS England and Biogen

02 May 2019 / Posted in: Treatments & Research

Read the flyer and letters that were sent urging these three organisations to work strenuously this week so that on May 8th, the NICE committee can endorse an agreement for access to nusinersen for all with SMA Types 1, 2 and 3.

Read full story

Urgent Call For Action - Please Contact Your MP Today About The NICE Committee Meeting on 8th May

01 May 2019 / Posted in: Treatments & Research

Following yesterday's announcement to say access to nusinersen is now to be considered at a private fourth NICE committee meeting, we need to pull out all the stops and ask our MPs to write to all parties urging them to reach an agreement on access for all.

Read full story

Update from NICE re Nusinersen

30 April 2019 / Posted in: Treatments & Research

Update from NICE re nusinersen: The outcome of discussions, following the meeting on 6th March, and the consequences for access to nusinersen, will be considered by the committee on Wednesday 8th May.

Read full story

'Corporate Reputation of Pharma, 2018' Global Report

18 April 2019 / Posted in: Treatments & Research

The 'Corporate Reputation of Pharma, 2018' Global report is based on the findings of a PatientView November 2018-February 2019 survey exploring the views of 1,500 patient groups worldwide.

Read full story

AveXis Data Reinforce Effectiveness of Zolgensma™ in Treating Spinal Muscular Atrophy (SMA) Type 1

17 April 2019 / Posted in: Treatments & Research

Interim data from Phase 3 clinical trial of Zolgensma (STR1VE) suggest that infants on the gene therapy product live longer and achieve significant developmental milestones.

Read full story

SMA Europe Reports on its Activities

16 April 2019 / Posted in: Treatments & Research

SMA UK is a member of SMA Europe which held its three-day AGM in Bucharest on 4th-6th April. There were reports on SMA Europe's achievements in the year to date, new organisations were welcomed and current and forthcoming plans were outlined.

Read full story